Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208) is a research paper published in JNCI Journal of the National Cancer Institute (2024). On theSindex it has a DataRank of 0.443. It has been cited 10 times, with 10 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0.0837
From 7 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 10 citers.
National Institutes of Health
Grant: U10CA180820
National Institutes of Health
Grant: U10CA180794
National Institutes of Health
Grant: U10CA180888
National Institutes of Health
Grant: UG1CA233320
National Institutes of Health
Grant: UG1CA233302
National Institutes of Health
Grant: UG1CA233337
National Institutes of Health
Grant: UG1CA189830
National Institutes of Health
Grant: UG1CA180830
National Institutes of Health
Grant: UG1CA233341
National Institutes of Health
Grant: P30CA014089
National Institutes of Health
Grant: P30CA072720
NCATS NIH HHS
Grant: UL1 TR001863
National Cancer Institute
Cancer Research Group
ECOG-ACRIN
ECOG-ACRIN
Cancer Research Group
FWCI
1.74
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals